Ribo Life Science-B (06938.HK) submits an application for a Phase I clinical trial of RBD3133 injection for the treatment of overweight and obesity.

Zhito Finance APP News: Ribo Life Science-B (06938.HK) announced that it has submitted an application in the European Union for a Phase I clinical trial of the company's INHBE-targeting siRNA product RBD3133 injection for the treatment indication of overweight and obesity.